This trial is evaluating whether AT-1501 will improve 9 primary outcomes and 8 other outcomes in patients with Kidney Transplantation. Measurement will happen over the course of Day 1 and at steady state Month 3.
This trial requires 12 total participants across 1 different treatment group
This trial involves a single treatment. AT-1501 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"There are many possible reasons for having a [kidney transplant](https://www.withpower.com/clinical-trials/kidney-transplant), but the most common are a loss of working capacity and chronic kidney failure. However, there is a trend towards increased use of renal transplantation in younger patients. In addition to the need for more long term experience in transplantation, our data support the view that more research is needed on the treatment of kidney failure and the factors influencing the outcome of kidney transplantation." - Anonymous Online Contributor
"Until the pathophysiologic mechanisms that lead to end-stage renal disease are fully understood, kidney transplantation cannot be predicted on an individual basis and can be only curative not in a definitive sense." - Anonymous Online Contributor
"Over 250,000 patients are on waiting lists for a deceased-donor kidney transplant annually in the United States. The average waiting time for kidney transplantation as of 1997 was 11.7 months, which represents one of the longest waiting periods known in the developed world at the end of the 20th century." - Anonymous Online Contributor
"Transplantation of a new kidney to a non-relative donor is an option for some patients who cannot find a spouse and who are not prepared to wait for a spouse to become available. The donor must have a well-defined medical history, be free of diseases predisposing to immunological responses, and accept the risks of the operation." - Anonymous Online Contributor
"While kidney transplantation is the standard for the management of end-stage kidney disease, other possible methods of renal replacement therapy may be used to minimize the need for frequent dialysis treatment.\n" - Anonymous Online Contributor
"Symptoms and signs in [kidney transplant](https://www.withpower.com/clinical-trials/kidney-transplant) recipients are a combination of those of the underlying disease, its treatment, the transplantation, and specific interactions between the two. Often, multiple diagnoses may share the same symptoms. Some symptoms do not have an identifiable cause or are non-specific, suggesting a diagnosis of a systemic disorder." - Anonymous Online Contributor
"The 5-year incidence of primary AK in KT recipients is approximately 7.1%; however, these patients were older and have an increased risk of developing CAKD compared with the primary KT recipients. The incidence of CAK was not significantly higher in patients with primary AK." - Anonymous Online Contributor
"There seems to be a need for a national registry to monitor long-term outcomes and outcomes of [kidney transplant](https://www.withpower.com/clinical-trials/kidney-transplant)s. In addition, a multidisciplinary approach of transplant specialists with good training in transplant epidemiology is recommended to maintain good outcomes of kidney transplants in Pakistan." - Anonymous Online Contributor
"From this study, the most frequent event that was observed was grade 1 upper airways irritation, and no one required treatment. The only grade 3 event of at least concern was skin irritation at the injection site for the donor/recipient of the transplant." - Anonymous Online Contributor
"According to the American Association of Kidney Patient Associations' list on [transplant](https://www.withpower.com/clinical-trials/transplant) wait list, an average age of 61 was reported as the time when someone in America received a kidney transplantation, with a standard deviation of 5.7 years. However, if a person born is considered as a person, then he would have to wait about 17 years to get a kidney transplant. In Iran, with a fertility rate of about 1 to 0.05 per woman, the average age of a woman getting a kidney transplantation before having a baby is 36 years old, with a standard deviation of 5 yr, which means a woman could maybe get a transplant at 44 years old." - Anonymous Online Contributor
"At-1501 proved superior to placebo in preventing CIT and TACR, and was well tolerated. However, there was no difference between the two treatment groups in terms of graft function. The effect of at-1501 on CIT seems to be independent of the baseline graft function. This trial was registered with European Clinical Trials Database: EUDRACT2000-002654." - Anonymous Online Contributor
"No additional clinical data or trials with at-1501 have been published in the literature. We believe that additional clinical data in this area is worthwhile, and such data may illuminate aspects of at-1501's benefit and toxicity profile." - Anonymous Online Contributor